J&J’s Tapentadol Raises Competitive Bar in Pain Market
Executive Summary
Johnson & Johnson's newly approved acute pain drug tapentadol will likely face more market competition from tramadol generics than the drug the company compared it to in Phase III studies - oxycodone, analysts say